Zacks: Analysts Expect Ultranyx Pharmaceutical Inc. (NASDAQ: RARE) to Report Quarterly Sales of $84.32 Million

Analysts expect Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get a rating) will announce sales of $84.32 million for the current fiscal quarter, Zacks Investment Research reports. Eight analysts provided earnings estimates for Ultragenyx Pharmaceutical, with estimates ranging from $78.50 million to $95.49 million. Ultragenyx Pharmaceutical reported sales of $99.40 million in the same quarter last year, suggesting a negative 15.2% year-over-year growth rate. The company is expected to release its next quarterly results after the market closes on Monday, January 1.

According to Zacks, analysts expect Ultranyx Pharmaceutical to report annual revenue of $378.09 million for the current fiscal year, with estimates ranging from $349.20 million to $423.92. millions of dollars. For the next fiscal year, analysts expect the company to record sales of $489.58 million, with estimates ranging from $373.66 million to $591.20 million. Zacks sales averages are an average average based on a survey of research companies that track Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) last released its quarterly results on Thursday, May 5. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($1.78) by ($0.41). The company posted revenue of $79.94 million in the quarter, versus analyst estimates of $84.25 million. Ultragenyx Pharmaceutical posted a negative return on equity of 44.24% and a negative net margin of 129.20%. Ultragenyx Pharmaceutical revenue decreased 19.6% compared to the same quarter last year. During the same period of the previous year, the company posted an EPS of ($2.03).

(A d)

Looking for the next disruptive Microcap stocks? These companies will be releasing their quarterly results very soon… And we’ve found 5 microcap stocks that could experience a surge in share price.

RARE has been the subject of several recent analyst reports. JPMorgan Chase & Co. upgraded Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a price target of $132.00 for the company in a Friday, February 11 report. Zacks Investment Research upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating and set a price target of $75.00 for the company in a Tuesday, February 15 report. Morgan Stanley lowered its price target on Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a Friday, Feb. 11 report. Credit Suisse Group upgraded Ultragenyx Pharmaceutical from a “neutral” rating to an “outperforming” rating and raised its share price target from $99.00 to $105.00 in a Wednesday, March 16 report. To finish, StockNews.com downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a Tuesday, April 26 report. Two investment analysts gave the stock a sell rating, three gave the company a hold rating and nine gave the company a buy rating. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of “Buy” and an average price target of $120.60.

In other news, Executive Vice President Thomas Richard Kassberg sold 10,281 shares of the company in a trade that took place on Friday, March 11. The stock was sold at an average price of $67.01, for a total value of $688,929.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available via the SEC website. Also, insider John Richard Pignon sold 4,498 shares of the company in a transaction that took place on Tuesday, March 1. The shares were sold at an average price of $66.62, for a total value of $299,656.76. Disclosure of this sale can be found here. Insiders have sold 22,764 shares of the company valued at $1,504,050 in the past three months. 6.70% of the shares are currently held by company insiders.

Institutional investors have recently been buying and selling shares of the company. Alpha Paradigm Partners LLC purchased a new equity stake in Ultragenyx Pharmaceutical in the fourth quarter worth approximately $113,000. Advisor Group Holdings Inc. increased its position in shares of Ultragenyx Pharmaceutical by 26.6% during the third quarter. Advisor Group Holdings Inc. now owns 1,612 shares of the biopharmaceutical company worth $146,000 after buying 339 additional shares in the last quarter. Harbor Capital Advisors Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical during the first quarter for a value of approximately $169,000. Trek Financial LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter for a value of approximately $205,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth approximately $207,000. Institutional investors and hedge funds own 97.49% of the company’s shares.

Shares of NASDAQ RARE opened at $66.43 on Friday. The company has a market capitalization of $4.61 billion, a PE ratio of -9.90 and a beta of 1.58. The company has a 50-day simple moving average of $72.32 and a two-hundred-day simple moving average of $75.11. Ultragenyx Pharmaceutical has a fifty-two week low of $61.21 and a fifty-two week high of $119.54.

About Ultranyx Pharmaceutical (Get a rating)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Read more

Get a Free Copy of Zacks’ Research Report on Ultragenyx Pharmaceutical (RARE)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Ultragenyx Pharmaceutical right now?

Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.

Although Ultragenyx Pharmaceutical currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here